Evidence map›Paper›PMID 31280962›Full record

ArticleCell2019

VEGAS as a Platform for Facile Directed Evolution in Mammalian Cells.

Justin G English, Reid H J Olsen, Katherine Lansu, Michael Patel, Karoline White, Adam S Cockrell, Darshan Singh, Ryan T Strachan, Daniel Wacker, Bryan L Roth

Erratum issuedAbstract read
In one paragraph

Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed.

  1. Review
  2. Anti-CRISPR-mediated continuous directed evolution of CRISPR-Cas9 in human cells.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Journal of the American Chemical Society · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. REPLACE-ing RNA through evolution.Nature chemical biology · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Selective optogenetic inhibition of GαProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Justin G EnglishDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27514, USA. Electronic address: jgenglis@email.unc.edu.
Reid H J OlsenDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27514, USA.
Katherine LansuDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27514, USA.
Michael PatelEshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27514, USA.
Karoline WhiteDepartment of Biology, University of North Carolina, Chapel Hill, NC 27514, USA.
Adam S CockrellDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC 27514, USA.
Darshan SinghDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27514, USA.
Ryan T StrachanDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27514, USA.
Daniel WackerDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27514, USA.
Bryan L RothDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27514, USA. Electronic address: bryan_roth@med.unc.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Illuminating the Druggable GPCR-omeU24DK116195 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L., SHOICHET, BRIAN K · 2017 to 2022
$14.3M
Molecular Details of Psychoactive Drug ActionsR01MH112205 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2017 to 2026
$6.1M
Mechanistic insights into LSD actions at 5-HT2A serotonin receptorsR37DA045657 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth · 2018 to 2026
$5.8M
DREADD2.0: AN ENHANCED CHEMOGENETIC TOOLKITU01MH105892 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JIN, JIAN, KASH, THOMAS L. · 2014 to 2016
$3.0M
NCI NIH HHS P30 CA016086NIDA NIH HHS R37 DA045657NIDDK NIH HHS U24 DK116195NIMH NIH HHS R01 MH112205NIMH NIH HHS U01 MH105892
6 · The paper itself

Abstract

Directed evolution, artificial selection toward designed objectives, is routinely used to develop new molecular tools and therapeutics. Successful directed molecular evolution campaigns repeatedly test diverse sequences with a designed selective pressure. Unicellular organisms and their viral pathogens are exceptional for this purpose and have been used for decades. However, many desirable targets of directed evolution perform poorly or unnaturally in unicellular backgrounds. Here, we present a system for facile directed evolution in mammalian cells. Using the RNA alphavirus Sindbis as a vector for heredity and diversity, we achieved 24-h selection cycles surpassing 10

Indexed as

Allosteric RegulationAmino Acid SequenceAnimalsDirected Molecular EvolutionFluorescence Resonance Energy TransferGenetic VectorsHEK293 CellsHumansMutationReceptors, G-Protein-CoupledSequence AlignmentSindbis VirusSingle-Domain AntibodiesTranscription FactorsReceptors, G-Protein-CoupledSingle-Domain AntibodiesTranscription Factorsartificial selectionGPCRG-protein coupled receptorsmammalian-directed evolutionmolecular pharmacologynanobodiestranscription factorsviral engineering

Identifiers

PMID31280962
PMCPMC6660416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.